2023-24 Scale-up project
Cheaper & globally distributed gene synthesis technology increases the risk that malicious actors could misuse this technology to create and modify biological agents. The incentives, standards, & technological approaches in place for screening orders & customers have not kept up with the pace & reach of synthesis technology. The administrative burden associated with screening orders has markedly increased.
This Common Mechanism (CM) provides: a secure & globally accessible system for screening orders; a more affordable and sustainable way for existing companies to maintain a state-of-the-art screening system; assurance that companies can screen while not losing their competitive edge in the global market; & opportunities for new companies to enter and compete in a secure synthesis market without forgoing security or developing their own screening capability.
We want a world in which bioscience and biotechnology can advance & flourish safely & responsibly. The International Biosecurity and Biosafety Initiative for Science (IBBIS) works collaboratively with global partners to strengthen biosecurity norms & develop innovative tools to uphold them. IBBIS was incubated by NTI, a non-profit global security organization focused on reducing nuclear and biological risks imperilling humanity.
“We know from experience that DNA synthesis can also be misused. An initiative like IBBIS can make sure that DNA synthesis is being used properly and not to create any kind of harm.”
Dr. Shyam Bishen, Head of Health & Healthcare, World Economic Forum